A new cure for river blindness and elephantiasis

W. DAVID HONG | January 29, 2019

article image
Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) are neglected tropical diseases (NTDs) that cause severe disability and affect more than 106 million people, according to the latest reports from WHO. These two NTDs are caused by parasitic roundworms, the filarial nematodes Onchocerca volvulus (onchocerciasis), Wuchereria  bancrofti, Brugia malayi, and Brugia timori (lymphatic filariasis). These diseases have long-term chronic impacts on the health and wellbeing of endemic communities, including economic burden, disabilities, mental health issues and social stigmas.

Spotlight

Sygnature Discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is the United Kingdom’s largest independent provider of integrated drug discovery resource and expertise.

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Comparing HydroxyChloroquine Trials

Article | April 3, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | April 3, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | April 3, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Spotlight

Sygnature Discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is the United Kingdom’s largest independent provider of integrated drug discovery resource and expertise.

Events